JP2013512678A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013512678A5 JP2013512678A5 JP2012542240A JP2012542240A JP2013512678A5 JP 2013512678 A5 JP2013512678 A5 JP 2013512678A5 JP 2012542240 A JP2012542240 A JP 2012542240A JP 2012542240 A JP2012542240 A JP 2012542240A JP 2013512678 A5 JP2013512678 A5 JP 2013512678A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- seq
- factor viii
- amino acids
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical class 0.000 claims description 159
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 130
- 229920001184 polypeptide Polymers 0.000 claims description 129
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 129
- 108010054218 Factor VIII Proteins 0.000 claims description 114
- 102000001690 Factor VIII Human genes 0.000 claims description 114
- 229960000301 factor viii Drugs 0.000 claims description 114
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 58
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 44
- 230000000694 effects Effects 0.000 claims description 30
- 208000032843 Hemorrhage Diseases 0.000 claims description 26
- 208000034158 bleeding Diseases 0.000 claims description 26
- 230000000740 bleeding effect Effects 0.000 claims description 26
- 238000001356 surgical procedure Methods 0.000 claims description 21
- 238000011287 therapeutic dose Methods 0.000 claims description 21
- 238000011084 recovery Methods 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 10
- 208000024891 symptom Diseases 0.000 claims description 9
- 208000014674 injury Diseases 0.000 claims description 5
- 238000007917 intracranial administration Methods 0.000 claims description 5
- 230000008733 trauma Effects 0.000 claims description 5
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 4
- 238000012217 deletion Methods 0.000 claims description 4
- 230000037430 deletion Effects 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims description 4
- 208000029836 Inguinal Hernia Diseases 0.000 claims description 3
- 210000000683 abdominal cavity Anatomy 0.000 claims description 3
- 238000007428 craniotomy Methods 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 238000013150 knee replacement Methods 0.000 claims description 3
- 238000002271 resection Methods 0.000 claims description 3
- 238000007483 tonsillectomy Methods 0.000 claims description 3
- 102000009027 Albumins Human genes 0.000 claims description 2
- 108010088751 Albumins Proteins 0.000 claims description 2
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 1
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 1
- 208000009292 Hemophilia A Diseases 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 238000002297 emergency surgery Methods 0.000 claims 1
- 230000013632 homeostatic process Effects 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 88
- 108010076504 Protein Sorting Signals Proteins 0.000 description 43
- 108010014173 Factor X Proteins 0.000 description 21
- 108090001015 cancer procoagulant Proteins 0.000 description 15
- 108010048049 Factor IXa Proteins 0.000 description 9
- 239000002157 polynucleotide Substances 0.000 description 8
- 102000040430 polynucleotide Human genes 0.000 description 8
- 108091033319 polynucleotide Proteins 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 4
- 108090000190 Thrombin Proteins 0.000 description 3
- 102000057593 human F8 Human genes 0.000 description 3
- 229960000900 human factor viii Drugs 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 206010072043 Central nervous system haemorrhage Diseases 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 2
- 206010019196 Head injury Diseases 0.000 description 2
- 206010028024 Mouth haemorrhage Diseases 0.000 description 2
- 206010028309 Muscle haemorrhage Diseases 0.000 description 2
- 208000009613 Oral Hemorrhage Diseases 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 210000000574 retroperitoneal space Anatomy 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 241000700605 Viruses Species 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26707009P | 2009-12-06 | 2009-12-06 | |
| US61/267,070 | 2009-12-06 | ||
| US28505409P | 2009-12-09 | 2009-12-09 | |
| US61/285,054 | 2009-12-09 | ||
| US30159210P | 2010-02-04 | 2010-02-04 | |
| US61/301,592 | 2010-02-04 | ||
| US36306510P | 2010-07-09 | 2010-07-09 | |
| US61/363,065 | 2010-07-09 | ||
| US37311310P | 2010-08-12 | 2010-08-12 | |
| US61/373,113 | 2010-08-12 | ||
| US41092910P | 2010-11-07 | 2010-11-07 | |
| US61/410,929 | 2010-11-07 | ||
| US41967610P | 2010-12-03 | 2010-12-03 | |
| US61/419,676 | 2010-12-03 | ||
| PCT/US2010/059136 WO2011069164A2 (en) | 2009-12-06 | 2010-12-06 | Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015012409A Division JP6062459B2 (ja) | 2009-12-06 | 2015-01-26 | 第ＶＩＩＩ−Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013512678A JP2013512678A (ja) | 2013-04-18 |
| JP2013512678A5 true JP2013512678A5 (https=) | 2013-12-26 |
| JP5903048B2 JP5903048B2 (ja) | 2016-04-13 |
Family
ID=44115536
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012542240A Active JP5903048B2 (ja) | 2009-12-06 | 2010-12-06 | 第ＶＩＩＩ−Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
| JP2015012409A Active JP6062459B2 (ja) | 2009-12-06 | 2015-01-26 | 第ＶＩＩＩ−Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
| JP2016209535A Active JP6385410B2 (ja) | 2009-12-06 | 2016-10-26 | 第ＶＩＩＩ−Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
| JP2017220060A Active JP6641340B2 (ja) | 2009-12-06 | 2017-11-15 | 第ＶＩＩＩ−Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
| JP2019202433A Withdrawn JP2020019821A (ja) | 2009-12-06 | 2019-11-07 | 第ＶＩＩＩ−Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
| JP2022020759A Active JP7244688B2 (ja) | 2009-12-06 | 2022-02-14 | 第ＶＩＩＩ－Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
| JP2023036392A Pending JP2023071969A (ja) | 2009-12-06 | 2023-03-09 | 第ＶＩＩＩ－Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
| JP2025037046A Pending JP2025083451A (ja) | 2009-12-06 | 2025-03-10 | 第ＶＩＩＩ－Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
Family Applications After (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015012409A Active JP6062459B2 (ja) | 2009-12-06 | 2015-01-26 | 第ＶＩＩＩ−Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
| JP2016209535A Active JP6385410B2 (ja) | 2009-12-06 | 2016-10-26 | 第ＶＩＩＩ−Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
| JP2017220060A Active JP6641340B2 (ja) | 2009-12-06 | 2017-11-15 | 第ＶＩＩＩ−Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
| JP2019202433A Withdrawn JP2020019821A (ja) | 2009-12-06 | 2019-11-07 | 第ＶＩＩＩ−Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
| JP2022020759A Active JP7244688B2 (ja) | 2009-12-06 | 2022-02-14 | 第ＶＩＩＩ－Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
| JP2023036392A Pending JP2023071969A (ja) | 2009-12-06 | 2023-03-09 | 第ＶＩＩＩ－Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
| JP2025037046A Pending JP2025083451A (ja) | 2009-12-06 | 2025-03-10 | 第ＶＩＩＩ－Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法 |
Country Status (30)
| Country | Link |
|---|---|
| US (5) | US9050318B2 (https=) |
| EP (4) | EP3326643B1 (https=) |
| JP (8) | JP5903048B2 (https=) |
| KR (1) | KR101770849B1 (https=) |
| CN (1) | CN102791285A (https=) |
| AU (6) | AU2010325787B2 (https=) |
| BR (1) | BR112012013502A2 (https=) |
| CA (2) | CA3121739A1 (https=) |
| CO (1) | CO6561782A2 (https=) |
| CY (2) | CY1119919T1 (https=) |
| DK (1) | DK2506868T3 (https=) |
| EA (2) | EA038618B1 (https=) |
| ES (2) | ES2659888T3 (https=) |
| HR (2) | HRP20180135T1 (https=) |
| HU (1) | HUE036233T2 (https=) |
| IL (2) | IL220204B (https=) |
| LT (1) | LT2506868T (https=) |
| ME (1) | ME02964B (https=) |
| MX (3) | MX353233B (https=) |
| MY (1) | MY159135A (https=) |
| NO (1) | NO2506868T3 (https=) |
| NZ (2) | NZ600709A (https=) |
| PL (2) | PL2506868T3 (https=) |
| PT (2) | PT2506868T (https=) |
| RS (1) | RS56957B1 (https=) |
| SG (3) | SG10201907152YA (https=) |
| SI (1) | SI2506868T1 (https=) |
| SM (1) | SMT201800099T1 (https=) |
| WO (1) | WO2011069164A2 (https=) |
| ZA (1) | ZA201204874B (https=) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6263355A (ja) * | 1985-09-13 | 1987-03-20 | Hitachi Ltd | バツテリバツクアツプｒａｍのチエツク方法 |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| ES2610356T3 (es) | 2009-02-03 | 2017-04-27 | Amunix Operating Inc. | Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos |
| CA2771999A1 (en) | 2009-08-24 | 2011-03-10 | Amunix Operating Inc. | Coagulation factor vii compositions and methods of making and using same |
| SI2506868T1 (en) * | 2009-12-06 | 2018-04-30 | Bioverativ Therapeutics Inc. | HYPER AND HYBRID POLYPETTIDES FACTOR VIII-FC AND METHODS FOR THEIR USE |
| TW201217527A (en) | 2010-07-09 | 2012-05-01 | Biogen Idec Hemophilia Inc | Processable single chain molecules and polypeptides made using same |
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2625189B1 (en) | 2010-10-01 | 2018-06-27 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| CA2813411C (en) | 2010-11-05 | 2016-08-02 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9486507B2 (en) | 2011-06-10 | 2016-11-08 | Biogen Ma Inc. | Pro-coagulant compounds and methods of use thereof |
| PT3513804T (pt) * | 2011-07-08 | 2022-06-02 | Bioverativ Therapeutics Inc | Polipéptidos fator viii híbridos e quiméricos, e métodos de utilização dos mesmos |
| WO2013016454A1 (en) | 2011-07-25 | 2013-01-31 | Biogen Idec Hemophilia Inc. | Assays to monitor bleeding disorders |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DE19216461T1 (de) | 2011-10-03 | 2021-10-07 | Modernatx, Inc. | Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon |
| CA3018046A1 (en) | 2011-12-16 | 2013-06-20 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| CN104271150A (zh) * | 2012-01-12 | 2015-01-07 | 比奥根艾迪克Ma公司 | 嵌合因子viii多肽及其用途 |
| EA038705B1 (ru) * | 2012-01-12 | 2021-10-07 | Биовератив Терапьютикс Инк. | Способы снижения иммуногенности фактора свёртывания крови viii у пациентов, получающих лечение фактором viii |
| EP2822577B1 (en) | 2012-02-15 | 2019-02-06 | Bioverativ Therapeutics Inc. | Recombinant factor viii proteins |
| JP6256882B2 (ja) * | 2012-02-15 | 2018-01-10 | アムニクス オペレーティング インコーポレイテッド | 第ｖｉｉｉ因子組成物、ならびに組成物の作製方法および用途 |
| WO2013151665A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| EP2836518B1 (en) | 2012-04-11 | 2019-01-02 | Bioverativ Therapeutics Inc. | Methods of detecting glycosaminoglycans |
| WO2013185113A1 (en) | 2012-06-08 | 2013-12-12 | Biogen Idec Ma Inc. | Procoagulant compounds |
| CA2875247A1 (en) | 2012-06-08 | 2013-12-12 | Biogen Idec Ma Inc. | Chimeric clotting factors |
| US10023628B2 (en) * | 2012-07-06 | 2018-07-17 | Bioverativ Therapeutics Inc. | Cell line expressing single chain factor VIII polypeptides and uses thereof |
| CN104661674A (zh) * | 2012-07-11 | 2015-05-27 | 阿穆尼克斯运营公司 | 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途 |
| US10001495B2 (en) | 2012-07-25 | 2018-06-19 | Bioverativ Therapeutics Inc. | Blood factor monitoring assay and uses thereof |
| HK1213767A1 (zh) | 2012-10-18 | 2016-07-15 | Bioverativ Therapeutics Inc. | 使用固定劑量凝血因子的方法 |
| HK1214539A1 (zh) * | 2012-10-30 | 2016-07-29 | Bioverativ Therapeutics Inc. | 應用viii因子多肽的方法 |
| PL2922554T3 (pl) | 2012-11-26 | 2022-06-20 | Modernatx, Inc. | Na zmodyfikowany na końcach |
| US10717965B2 (en) | 2013-01-10 | 2020-07-21 | Gloriana Therapeutics, Inc. | Mammalian cell culture-produced neublastin antibodies |
| WO2014127215A1 (en) * | 2013-02-15 | 2014-08-21 | Biogen Idec Ma Inc. | Optimized factor viii gene |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US9090697B2 (en) * | 2013-03-15 | 2015-07-28 | Bayer Healthcare Llc | Methods for treating bleeding disorders |
| EP4122487A1 (en) * | 2013-03-15 | 2023-01-25 | Bioverativ Therapeutics Inc. | Factor viii polypeptide formulations |
| US10364288B2 (en) | 2013-05-24 | 2019-07-30 | Biogen Ma Inc. | Anti-GPIIB/IIIA antibodies or uses thereof |
| TW201536811A (zh) * | 2013-05-31 | 2015-10-01 | Biogen Idec Inc | 嵌合ｆｖｉｉ－ｘｔｅｎ分子及其用途 |
| SG11201510515YA (en) * | 2013-06-20 | 2016-01-28 | Baxalta Inc | Providing a pharmacokinetic drug dosing regime |
| EP3013359A4 (en) * | 2013-06-28 | 2017-01-25 | Biogen MA Inc. | Thrombin cleavable linker |
| CN113817069A (zh) * | 2013-06-28 | 2021-12-21 | 比奥贝拉蒂治疗公司 | 具有xten的凝血酶可裂解连接子和其用途 |
| WO2015015448A2 (en) | 2013-07-31 | 2015-02-05 | Rinat Neuroscience Corp. | Engineered polypeptide conjugates |
| TW202003554A (zh) | 2013-08-14 | 2020-01-16 | 美商百歐維拉提夫治療公司 | 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途 |
| US20160311885A1 (en) | 2013-08-14 | 2016-10-27 | Biogen Ma Inc. | Recombinant factor viii proteins |
| HUE057005T2 (hu) | 2013-09-25 | 2022-04-28 | Bioverativ Therapeutics Inc | Oszlopon történõ vírusinaktiváló eljárások |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| EP3065769A4 (en) | 2013-11-08 | 2017-05-31 | Biogen MA Inc. | Procoagulant fusion compound |
| US10325687B2 (en) * | 2013-12-06 | 2019-06-18 | Bioverativ Therapeutics Inc. | Population pharmacokinetics tools and uses thereof |
| WO2015095809A1 (en) | 2013-12-20 | 2015-06-25 | Biogen Idec Ma Inc. | Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality |
| AU2015204646B2 (en) | 2014-01-10 | 2020-08-27 | Bioverativ Therapeutics Inc. | Factor VIII chimeric proteins and uses thereof |
| WO2015120056A1 (en) | 2014-02-04 | 2015-08-13 | Biogen Ma Inc. | Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications |
| WO2015148454A1 (en) * | 2014-03-28 | 2015-10-01 | Asklepios Biopharmaceutical, Inc. | Optimized and modified factor viii genes for gene therapy |
| PT3134127T (pt) | 2014-04-25 | 2020-04-09 | Rinat Neuroscience Corp | Conjugados de anticorpo-fármaco com alta carga de fármaco |
| US11008561B2 (en) | 2014-06-30 | 2021-05-18 | Bioverativ Therapeutics Inc. | Optimized factor IX gene |
| BR112017007765B1 (pt) | 2014-10-14 | 2023-10-03 | Halozyme, Inc | Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo |
| MA40835A (fr) | 2014-10-23 | 2017-08-29 | Biogen Ma Inc | Anticorps anti-gpiib/iiia et leurs utilisations |
| MA40864A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères |
| MA40861A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
| EA201890423A1 (ru) | 2015-08-03 | 2018-07-31 | Биовератив Терапьютикс Инк. | Слитые белки фактора ix, способы их получения и применения |
| WO2017070167A1 (en) | 2015-10-20 | 2017-04-27 | The University Of North Carolina At Chapel Hill | Methods and compositions for modified factor ix fusion proteins |
| CA3012695A1 (en) | 2016-02-01 | 2017-08-10 | Bioverativ Therapeutics Inc. | Optimized factor viii genes |
| CA3020346A1 (en) | 2016-04-15 | 2017-10-19 | Baxalta Incorporated | Method and apparatus for providing a pharmacokinetic drug dosing regimen |
| TW201739448A (zh) * | 2016-05-06 | 2017-11-16 | 安成生物科技股份有限公司 | 用於治療及/或預防血液相關疾病之方法及配方 |
| WO2017222337A1 (ko) | 2016-06-24 | 2017-12-28 | 재단법인 목암생명과학연구소 | Fviii 및 vwf 인자를 포함하는 키메라 단백질 및 그 용도 |
| KR20190077306A (ko) | 2016-08-05 | 2019-07-03 | 메디뮨 엘엘씨 | 항-o2 항체 및 이의 용도 |
| CN106279437B (zh) * | 2016-08-19 | 2017-10-31 | 安源医药科技（上海）有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
| CN106317226B (zh) | 2016-08-19 | 2017-09-05 | 安源医药科技（上海）有限公司 | 用于构建融合蛋白的连接肽 |
| SG11201903063UA (en) | 2016-10-19 | 2019-05-30 | Medimmune Llc | Anti-o1 antibodies and uses thereof |
| JP2019536794A (ja) | 2016-12-02 | 2019-12-19 | バイオベラティブ セラピューティクス インコーポレイテッド | 凝固因子に対する免疫寛容を誘導する方法 |
| MX2019006444A (es) | 2016-12-02 | 2019-10-30 | Bioverativ Therapeutics Inc | Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos. |
| CN108239151B (zh) * | 2016-12-23 | 2020-07-03 | 海门晟斯生物制药有限公司 | 重组单链人FVIII-Fc融合蛋白及其应用 |
| US10896749B2 (en) | 2017-01-27 | 2021-01-19 | Shire Human Genetic Therapies, Inc. | Drug monitoring tool |
| EA201991768A1 (ru) | 2017-01-31 | 2020-01-22 | Байоверетив Терапьютикс Инк. | Слитые белки на основе фактора ix и способы их получения и пути применения |
| PL3793588T3 (pl) | 2018-05-18 | 2025-09-01 | Bioverativ Therapeutics Inc. | Sposoby leczenia hemofilii a |
| EP3802610A1 (en) | 2018-06-05 | 2021-04-14 | Amgen Inc. | Modulating antibody dependent cellular phagocytosis |
| CA3110530A1 (en) | 2018-09-11 | 2020-03-19 | Amgen Inc. | Methods of modulating antibody-dependent cell-mediated cytotoxicity |
| WO2020086408A1 (en) | 2018-10-26 | 2020-04-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A high-yield perfusion-based transient gene expression bioprocess |
| JP7644007B2 (ja) | 2018-12-06 | 2025-03-11 | バイオベラティブ セラピューティクス インコーポレイテッド | 第ｉｘ因子を発現するレンチウイルスベクターの使用 |
| CN114007637A (zh) | 2019-06-19 | 2022-02-01 | 比奥维拉迪维治疗股份有限公司 | 用于治疗血友病和低骨矿物质密度的重组因子viii-fc |
| KR20220097891A (ko) | 2019-09-30 | 2022-07-08 | 바이오버라티브 테라퓨틱스 인크. | 렌티바이러스 벡터 제형 |
| MX2023000156A (es) | 2020-06-24 | 2023-02-16 | Bioverativ Therapeutics Inc | Metodos para la eliminacion de factor viii libre de preparaciones de vectores lentivirales modificados para expresar dicha proteina. |
| AU2023261711A1 (en) * | 2022-04-28 | 2024-11-21 | Joint Stock Company "Biocad" | Isolated nucleic acid that encodes fusion protein based on fviii-bdd and on heterologous signal peptide |
| CN114989307B (zh) * | 2022-05-11 | 2023-08-01 | 华兰生物工程股份有限公司 | 一种重组人凝血因子Ⅷ-Fc融合蛋白及制备方法 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235881A (en) * | 1978-12-04 | 1980-11-25 | Cort Joseph H | Method for producing high potency factor VIII |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| ES8801674A1 (es) | 1985-04-12 | 1988-02-16 | Genetics Inst | Un procedimiento para la preparacion de una proteina que presenta actividad procoagulante. |
| KR910006424B1 (ko) | 1985-08-21 | 1991-08-24 | 인코텍스 비.브이 | 편성브리프(brief) 제조방법 |
| DE3785102T2 (de) | 1986-01-03 | 1993-07-22 | Genetics Inst | Verfahren zur herstellung von faktor-viii:c-typ-proteinen. |
| US5595886A (en) | 1986-01-27 | 1997-01-21 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
| US5543502A (en) | 1986-06-24 | 1996-08-06 | Novo Nordisk A/S | Process for producing a coagulation active complex of factor VIII fragments |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| CA1331157C (en) | 1987-04-06 | 1994-08-02 | Randal J. Kaufman | Method for producing factor viii:c-type proteins |
| US6060447A (en) | 1987-05-19 | 2000-05-09 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
| US6346513B1 (en) | 1987-06-12 | 2002-02-12 | Baxter Trading Gmbh | Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
| IL86693A (en) | 1987-06-12 | 1994-06-24 | Stichting Centraal Lab | Proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them |
| DE3720246A1 (de) | 1987-06-19 | 1988-12-29 | Behringwerke Ag | Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet |
| FR2619314B1 (fr) | 1987-08-11 | 1990-06-15 | Transgene Sa | Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant |
| US4994371A (en) | 1987-08-28 | 1991-02-19 | Davie Earl W | DNA preparation of Christmas factor and use of DNA sequences |
| US5004803A (en) | 1988-11-14 | 1991-04-02 | Genetics Institute, Inc. | Production of procoagulant proteins |
| SE465222C5 (sv) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
| CA2078721A1 (en) | 1991-09-24 | 1993-03-25 | Hiroshi Yonemura | Process for preparing human coagulation factor viii protein complex |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US6376463B1 (en) | 1992-04-07 | 2002-04-23 | Emory University | Modified factor VIII |
| US5364771A (en) | 1992-04-07 | 1994-11-15 | Emory University | Hybrid human/porcine factor VIII |
| US5859204A (en) | 1992-04-07 | 1999-01-12 | Emory University | Modified factor VIII |
| US5563045A (en) | 1992-11-13 | 1996-10-08 | Genetics Institute, Inc. | Chimeric procoagulant proteins |
| SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
| US6818439B1 (en) | 1994-12-30 | 2004-11-16 | Chiron Corporation | Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders |
| SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
| US6458563B1 (en) | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
| CA2225189C (en) | 1997-03-06 | 2010-05-25 | Queen's University At Kingston | Canine factor viii gene, protein and methods of use |
| HUP0204475A2 (en) | 2000-02-11 | 2003-04-28 | Merck Patent Gmbh | Enhancing the circulating half-life of antibody-based fusion proteins |
| EP2213743A1 (en) | 2000-04-12 | 2010-08-04 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| BR0207007A (pt) * | 2001-02-05 | 2004-02-17 | Novo Nordisk Healthcare Ag | Composição farmcêutica, kit, usos de uma preparação e de uma composição, e, métodos para tratar de episódios de hemorragia em um paciente, para reduzir o tempo de coagulação em um paciente, para intensificar a hemostasia em um paciente para reduzir o número de administrações da proteìna do fator de coagulação necessário para deter a hemorragia e manter a hemostasia em um paciente, para reduzir a quantidade de proteìna do fator de coagulação administrada necessária para deter a hemorragia e manter a hemostasia em um paciente, para prolongar o tempo de lise do coágulo em um paciente, para aumentar a resistência do coágulo em paciente e para intensificar a formação de coágulo de fibrina em um paciente |
| AU2002364586A1 (en) | 2001-12-21 | 2003-07-30 | Delta Biotechnology Limited | Albumin fusion proteins |
| US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
| EP1444986A1 (en) * | 2003-02-07 | 2004-08-11 | Aventis Behring GmbH | Pharmaceutical preparation for the improved treatment of blood-clotting disorders |
| TWI353991B (en) * | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
| PL2298347T3 (pl) * | 2003-05-06 | 2016-03-31 | Bioverativ Therapeutics Inc | Białka chimeryczne czynnika krzepnięcia do leczenia zaburzenia hemostazy |
| CA2530980A1 (en) * | 2003-06-19 | 2005-01-20 | Tanox, Inc. | Tissue factor-specific antibodies for preventing or treating acute lung injury or acute respiratory distress syndrome |
| US7211559B2 (en) | 2003-10-31 | 2007-05-01 | University Of Maryland, Baltimore | Factor VIII compositions and methods |
| PT2363414T (pt) | 2004-11-12 | 2022-08-04 | Bayer Healthcare Llc | Modificação de fviii direcionada a sítio |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| AU2007223855B2 (en) | 2006-03-06 | 2013-05-16 | Amunix Operating Inc. | Unstructured recombinant polymers and uses thereof |
| AU2007245190B2 (en) * | 2006-03-31 | 2011-07-21 | Takeda Pharmaceutical Company Limited | Pegylated factor VIII |
| CA2673459C (en) | 2006-12-22 | 2016-09-13 | Stefan Schulte | Modified coagulation factors with prolonged in vivo half-life |
| JP2010536341A (ja) | 2007-08-15 | 2010-12-02 | アムニクス， インコーポレイテッド | 生物学的に活性なポリペプチドの特性を改変するための組成物および方法 |
| PL2257311T3 (pl) * | 2008-02-27 | 2014-09-30 | Novo Nordisk As | Koniugaty cząsteczek czynnika VIII |
| US8800831B2 (en) | 2009-08-19 | 2014-08-12 | Larry A. Gray | Multi-purpose rack and method thereof |
| ES2610356T3 (es) | 2009-02-03 | 2017-04-27 | Amunix Operating Inc. | Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos |
| JP5739865B2 (ja) * | 2009-03-24 | 2015-06-24 | バイエル・ヘルスケア・エルエルシー | 第ｖｉｉｉ因子変異体および使用の方法 |
| GB0908515D0 (en) | 2009-05-18 | 2009-06-24 | Apitope Technology Bristol Ltd | Peptide |
| SI2506868T1 (en) | 2009-12-06 | 2018-04-30 | Bioverativ Therapeutics Inc. | HYPER AND HYBRID POLYPETTIDES FACTOR VIII-FC AND METHODS FOR THEIR USE |
| PT3513804T (pt) * | 2011-07-08 | 2022-06-02 | Bioverativ Therapeutics Inc | Polipéptidos fator viii híbridos e quiméricos, e métodos de utilização dos mesmos |
| EA038705B1 (ru) * | 2012-01-12 | 2021-10-07 | Биовератив Терапьютикс Инк. | Способы снижения иммуногенности фактора свёртывания крови viii у пациентов, получающих лечение фактором viii |
| EP4122487A1 (en) * | 2013-03-15 | 2023-01-25 | Bioverativ Therapeutics Inc. | Factor viii polypeptide formulations |
| JP6083911B2 (ja) | 2014-12-19 | 2017-02-22 | 花王株式会社 | 吸収性物品 |
-
2010
- 2010-12-06 SI SI201031628T patent/SI2506868T1/en unknown
- 2010-12-06 EP EP17194648.6A patent/EP3326643B1/en active Active
- 2010-12-06 ME MEP-2018-40A patent/ME02964B/me unknown
- 2010-12-06 EA EA201691109A patent/EA038618B1/ru unknown
- 2010-12-06 MX MX2016000039A patent/MX353233B/es unknown
- 2010-12-06 SM SM20180099T patent/SMT201800099T1/it unknown
- 2010-12-06 EP EP24152910.6A patent/EP4382170A3/en active Pending
- 2010-12-06 LT LTEP10835255.0T patent/LT2506868T/lt unknown
- 2010-12-06 MY MYPI2012002429A patent/MY159135A/en unknown
- 2010-12-06 PL PL10835255T patent/PL2506868T3/pl unknown
- 2010-12-06 SG SG10201907152YA patent/SG10201907152YA/en unknown
- 2010-12-06 AU AU2010325787A patent/AU2010325787B2/en active Active
- 2010-12-06 ES ES10835255.0T patent/ES2659888T3/es active Active
- 2010-12-06 HR HRP20180135TT patent/HRP20180135T1/hr unknown
- 2010-12-06 NZ NZ600709A patent/NZ600709A/en unknown
- 2010-12-06 KR KR1020127017595A patent/KR101770849B1/ko active Active
- 2010-12-06 CN CN2010800629507A patent/CN102791285A/zh active Pending
- 2010-12-06 PT PT108352550T patent/PT2506868T/pt unknown
- 2010-12-06 NO NO10835255A patent/NO2506868T3/no unknown
- 2010-12-06 ES ES17194648T patent/ES2880038T3/es active Active
- 2010-12-06 MX MX2012006347A patent/MX336830B/es active IP Right Grant
- 2010-12-06 SG SG10201408049SA patent/SG10201408049SA/en unknown
- 2010-12-06 NZ NZ703153A patent/NZ703153A/en unknown
- 2010-12-06 RS RS20180182A patent/RS56957B1/sr unknown
- 2010-12-06 HU HUE10835255A patent/HUE036233T2/hu unknown
- 2010-12-06 JP JP2012542240A patent/JP5903048B2/ja active Active
- 2010-12-06 CA CA3121739A patent/CA3121739A1/en active Pending
- 2010-12-06 MX MX2018000089A patent/MX382693B/es unknown
- 2010-12-06 DK DK10835255.0T patent/DK2506868T3/da active
- 2010-12-06 EP EP21161784.0A patent/EP3906937A1/en not_active Ceased
- 2010-12-06 US US13/513,424 patent/US9050318B2/en active Active
- 2010-12-06 CA CA2782424A patent/CA2782424C/en active Active
- 2010-12-06 PL PL17194648T patent/PL3326643T3/pl unknown
- 2010-12-06 SG SG2012039640A patent/SG181130A1/en unknown
- 2010-12-06 EA EA201290443A patent/EA025416B1/ru not_active IP Right Cessation
- 2010-12-06 BR BR112012013502A patent/BR112012013502A2/pt not_active Application Discontinuation
- 2010-12-06 EP EP10835255.0A patent/EP2506868B1/en active Active
- 2010-12-06 PT PT171946486T patent/PT3326643T/pt unknown
- 2010-12-06 WO PCT/US2010/059136 patent/WO2011069164A2/en not_active Ceased
-
2012
- 2012-06-06 IL IL220204A patent/IL220204B/en active IP Right Grant
- 2012-06-29 CO CO12109855A patent/CO6561782A2/es unknown
- 2012-06-29 ZA ZA2012/04874A patent/ZA201204874B/en unknown
-
2013
- 2013-03-11 US US13/793,783 patent/US9241978B2/en active Active
-
2015
- 2015-01-26 JP JP2015012409A patent/JP6062459B2/ja active Active
- 2015-12-09 US US14/964,289 patent/US20160199455A1/en not_active Abandoned
-
2016
- 2016-08-11 AU AU2016213822A patent/AU2016213822B2/en active Active
- 2016-10-26 JP JP2016209535A patent/JP6385410B2/ja active Active
-
2017
- 2017-11-15 JP JP2017220060A patent/JP6641340B2/ja active Active
- 2017-11-30 AU AU2017268648A patent/AU2017268648B2/en active Active
-
2018
- 2018-02-14 CY CY20181100182T patent/CY1119919T1/el unknown
- 2018-07-25 IL IL260769A patent/IL260769B/en active IP Right Grant
-
2019
- 2019-02-07 US US16/270,302 patent/US11266720B2/en active Active
- 2019-04-29 AU AU2019202969A patent/AU2019202969A1/en not_active Abandoned
- 2019-11-07 JP JP2019202433A patent/JP2020019821A/ja not_active Withdrawn
-
2021
- 2021-05-07 AU AU2021202912A patent/AU2021202912B2/en active Active
- 2021-06-28 HR HRP20211010TT patent/HRP20211010T1/hr unknown
- 2021-07-07 CY CY20211100615T patent/CY1124888T1/el unknown
-
2022
- 2022-01-28 US US17/587,941 patent/US20220265780A1/en active Pending
- 2022-02-14 JP JP2022020759A patent/JP7244688B2/ja active Active
-
2023
- 2023-03-09 JP JP2023036392A patent/JP2023071969A/ja active Pending
-
2024
- 2024-10-30 AU AU2024227757A patent/AU2024227757A1/en active Pending
-
2025
- 2025-03-10 JP JP2025037046A patent/JP2025083451A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013512678A5 (https=) | ||
| JP2013534426A5 (https=) | ||
| JP2022051964A5 (https=) | ||
| JP2012529296A5 (https=) | ||
| CN102906120B (zh) | 重组人g-csf二聚体及其在治疗神经系统疾病中的用途 | |
| EP2823823B1 (en) | Polypeptides for the preparation of drugs for treatment or prevention of rheumatoid arthritis | |
| EA021425B1 (ru) | Мутанты fgf21 и их применение | |
| KR20060023968A (ko) | 중증 급성 호흡기 증후군(ｓａｒｓ)의 치료를 위한 조성물및 방법 | |
| JP2014506787A5 (https=) | ||
| US8501680B2 (en) | Antagonists against interaction of PF4 and RANTES | |
| JP2007536891A5 (https=) | ||
| JP2016535015A (ja) | 長期活性型ポリペプチドならびに当該ポリペプチドの製造方法および投与方法 | |
| EP3647320B1 (en) | Acetylcholine receptor-binding peptide | |
| US20230055021A1 (en) | Methods for treating psychiatric disorders or symptoms thereof using ncam peptide mimetics | |
| JP7016125B2 (ja) | 脳梗塞の治療薬 | |
| CN104640557A (zh) | 骨保护素衍生的组合物及其用途 | |
| Overton et al. | Engineered gcn4 trimerization motif | |
| KR20260035821A (ko) | 조작된 gcn4 삼량체화 모티프 | |
| CN121555454A (zh) | 抗黄病毒蛋白或多肽及其用途 | |
| HK40115251A (zh) | 用神经调节蛋白-1融合蛋白治疗纤维化及心律失常的方法 | |
| JP5439007B2 (ja) | 血管内皮細胞増殖因子阻害剤及び抗癌剤 | |
| CN101469028A (zh) | 肿瘤坏死因子受体-免疫球蛋白的融合蛋白用于肺癌药物的用途 | |
| HK1160650A (en) | Antagonists against interaction of pf4 and rantes |